[
    "{\"step_by_step_thinking\": \"The documents provide evidence that nintedanib, a tyrosine kinase inhibitor, has been approved for the treatment of idiopathic pulmonary fibrosis and has shown effectiveness in slowing disease progression in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). It has been shown to reduce the rate of decline in forced vital capacity, which is a measure of lung function. The drug has been granted priority review designation by the FDA and has received marketing approval in the United States and Japan for the treatment of SSc-ILD. Therefore, it can be concluded that nintedanib holds promise for lung disease associated with systemic sclerosis.\", \"answer_choice\": \"A\"}"
]